STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 January 2003 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On 28 November 1996, the European Commission approved three Variations (Type I, 60 days 
procedure) for the following changes: 
- 
- 
- 
Manufacturer of active substance; 
Batch size of active substance; 
Test procedure of active substance. 
On  20  January  1997  (dated  on  notification  4  September  1996),  the  European  Commission 
approved  the  transfer  of  the  Marketing  Authorisation  Holder  from  Organon  Ireland  to  N.V. 
Organon,  The  Netherlands.  The  relevant  amendments  have  been  incorporated  in  the  relevant 
sections of the Commission Decision and of this EPAR. 
On 3 April 1997, the European Commission approved three Variations (Type I following type 
II) for the addition of new batch release sites. The relevant amendments have been incorporated 
in the relevant sections of the Commission Decision and of this EPAR 
On 5 October 1998, the European Commission approved a Variation (Type II) for the following 
changes: amendments to the SPC and PL in order to give additional guidance to avoid injection 
of large volumes and to reduce pain at injection sites. Amendments have been incorporated in 
the relevant sections of the Commission Decision and of this EPAR. 
On 26 April 1999, the European Commission approved an Annex II application (Extension of 
the  Marketing  Authorisation)  for  7  additional  strengths/pharmaceutical  forms.  Amendments 
have been incorporated in the relevant sections of the Commission Decision and of this EPAR. 
Pursuant to article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation Holder notified the EMEA on 5 May 1999 of their intention to introduce changes 
to an aspect  of the labelling not  connected to  the  Summary of  Product Characteristics. On 28 
May  1999,  the  EMEA  notified  the  European  Commission  that  the  changes  were  accepted. 
Amendments to Annex IIIA were required and the Commission Decision was issued on 8 July 
1999. 
The CPMP issued on 23 September 1999 a positive Opinion on a Type II variation relating to a 
change in the release testing of the active substance. The Commission Decision was amended 
on 22 December 1999. 
The CPMP issued on 14 December 1999 a positive Notification on a Type I variation relating to 
a change in the release testing of the active substance. The Commission Decision was amended 
on 22 December 1999. 
The  CPMP  issued  on  23  September  1999  a  positive  Opinion  on  an  application  in  accordance 
with  Annex  II  to  Commission  Regulation  (EC)  No.  542/95,  as  amended  for  2  additional 
strengths (multidose preparations). The corresponding Commission Decision was issued on 10 
February 2000.   
The CPMP issued on 23 September 1999 a positive Opinion on a Type II variation relating to 
amendments  to  the  Summary  of  Product  Characteristics  and  Package  Leaflet  to  update  the 
posology section. The Commission Decision was amended on 21 February 2000. 
Pursuant to article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation Holder notified the EMEA on 24 September 1999 of their intention to introduce 
changes  to  an  aspect  of  the  Labelling  and  Package  Leaflet  not  connected  to  the  Summary  of 
1/4 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product  Characteristics.  On  21  October  1999,  the  EMEA  notified  the  European  Commission 
that the changes were accepted. Amendments to Annex III were required and the Commission 
Decision was issued on 21 February 2000. 
Pursuant to article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation  Holder  notified  the  EMEA  on  29  February  2000  of  their  intention  to  introduce 
changes to an aspect of the Labelling not connected to the Summary of Product Characteristics. 
On 7 April 2000, the EMEA notified the European Commission that the changes were accepted. 
Amendments to Annex IIIA were required and the Commission Decision was issued on 11 July 
2000. 
The CPMP issued on 29 June 2000 a positive Opinion on a Type II variation to include an extra 
precaution  regarding  a  possible  increased  risk  for  thrombosis  in  women  with  recognised  risk 
factors in the Summary of Product Characteristics and Package Leaflet. Secondly, a sentence on 
possible interaction of Puregon and GnRH agonists was adapted to reflect the recent approval of 
GnRH antagonists. Thirdly, in the SPC for the powder and solvent for solution for injection, a 
warning on possible hypersensitivity and a statement on antibody formation were deleted. This 
was done to bring the text for the powder and solvent for solution for injection, in line with the 
recently approved text for the solution for injection. The Commission Decision was amended on 
8 December 2000. 
The  CPMP  issued  on  27  June  2000  a  positive  Opinion  on  a  Type  II  variation  to  include  a 
change  in  storage  conditions  for  the  Puregon  solution  for  injection  (vials  and  multidose 
cartridges) in the Summary of Product Characteristics, Labelling and Package Leaflet. Stability 
data  were  provided  to  justify  that  the  product  can  be  stored  below  25°C  for  a  maximum  of  3 
months. The Commission Decision was amended on 8 December 2000. 
The EMEA issued on 25 July 2000 a positive Notification on a Type I variation for the addition 
of  a  second  manufacturing  site  for  Puregon  solution  for  injection.  The  Commission  Decision 
was amended on 28 August 2000. 
The  CPMP  issued  on  28  August  2000  a  positive  Opinion  on  a  Type  II  variation  concerning 
changes in test methods and release specifications for the active substance of Puregon solution 
for injection in cartridges. The Commission Decision was amended on 19 January 2001. 
The  EMEA  issued  on  22  September  2000  a  positive  Notification  on  a  Type  I  variation 
concerning a change in the in-process control for Puregon solution for injection in vials. 
The EMEA issued on 10 October 2000 a positive Notification on a Type I variation concerning 
the  deletion  of  one  of  the  manufacturing  sites  responsible  for  batch  release.  The  Commission 
Decision was issued on 15 January 2001. 
The CPMP issued on 14 December 2000 a positive Opinion on a Type II variation concerning 
the addition of a new indication for Puregon (all strengths and presentations), namely treatment 
of  male  subjects  who  suffer  from  deficient  spermatogenesis  due  to  hypogonadotropic 
hypogonadism. Several sections of the Summary of Product Characteristics and Package Leaflet 
have been amended and the product information has been brought in line with the current QRD 
template. In addition, the instructions for ‘intramuscular administration’ in the Package Leaflet 
for  the  ‘Powder  and  solvent  for  solution  for  injection’  presentations,  have  been  changed  in 
accordance with the instructions in the approved Package Leaflet for the ‘Solution for injection’ 
presentations. The Commission Decision was amended on 10 April 2001. 
The CPMP issued on 29 March 2001 a positive Opinion on an application for a renewal of the 
Marketing  Authorisation  for  Puregon.  The  Commission  Decision  was  amended  on  26  July 
2001. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
2/4 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
The CPMP issued on 29 March 2001 a positive Opinion on a Type II variation concerning the 
demonstration  of  compliance  with  the  Commission  Directive  1999/82/EC  and  the  Note  for 
Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via 
medicinal  products  (CPMP/BWP/1230/98  rev.1).  The  Commission  Decision  was  amended  on 
10 April 2001. 
On 28 March 2001, the Marketing Authorisation Holder submitted an application for a Type II 
variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The 
MAH applied for modification of the Summary of product Characteristics and package leaflet 
following the first 5-year renewal of the marketing authorisation. The CPMP adopted a positive 
Opinion for this variation on 27 June 2001. The respective Commission Decision was issued on 
5 February 2002. 
On 11 June 2001 the Marketing Authorisation Holder submitted to the EMEA an application for 
a Type I variation in accordance with Article 4 of European Commission Regulation (EC) No. 
542/95, as amended. The scope of this variation was to extend the shelf life as foreseen at the 
time of authorisation. The EMEA notified the European Commission on 13 July 2001 that the 
variation was accepted. Amendments to the Annex I was required and the Commission Decision 
was issued on 18 October 2001. 
On 29 October 2001 the Marketing Authorisation Holder submitted to the EMEA a notification 
according to article 10(3) of Council Directive No. 92/27/EEC to introduce changes to an aspect 
of the labelling not connected to the Summary of Product Characteristics. The procedure started 
on 31 October 2001. The EMEA notified the European Commission on 31 October 2001. The 
respective Commission Decision was issued on 8 March 2002. 
On  12  November  2001  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a Type II variation in accordance with Article 6 of Commission Regulation (EC) 
No.  542/95,  as  amended.  The  scope  of  this  variation  was  a  change  of  test  methods  and/or 
specifications  for  the  active  substance.  The  procedure  started  on  16  November  2001.  The 
EMEA notified the European Commission on 21 February 2002 that the variation was accepted 
and did not require any amendment to the Community Marketing Authorisation. The respective 
Commission Decision was issued on 19 March 2002. 
On 2 January 2002 the Marketing Authorisation Holder submitted to the EMEA an application 
for  a  Type  II  variation  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No. 
542/95, as amended. The scope of this variation was a change in the test procedure of the active 
substance  and/or  specifications  for  the  active  substance.  The  procedure  started  on  18  January 
2002.  The  EMEA  notified  the  European  Commission  on  30  May  2002  that  the  variation  was 
accepted and did not require any amendment to the Community Marketing Authorisation. 
On  12  February  2002  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a Type I variation in accordance with Article 4 of Commission Regulation (EC) 
No. 542/95, as amended. The scope of this variation was to change in the test procedure of the 
active substance. The procedure started on 22 February 2002. The EMEA notified the European 
Commission  on  27  June  2002  that  the  variation  was  accepted  and  did  not  require  any 
amendment to the Community Marketing Authorisation. 
On  27  February  2002  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a Type I variation in accordance with Article 4 of Commission Regulation (EC) 
No.  542/95,  as  amended.  The  scope  of  this  variation  was  a  minor  change  of  manufacturing 
process of the active substance. The procedure started on 4 March 2002. The EMEA notified the 
European Commission on 30 May 2002 that the variation was accepted and did not require any 
amendment to the Community Marketing Authorisation. 
3/4 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
On 19  April 2002 the Marketing  Authorisation Holder submitted to the EMEA an application 
for  a  Type  II  variation  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No. 
542/95, as amended. The scope of this variation was to update section 4.4 of the Summary of 
Product  Characteristics  (SPC)  and  section  2  of  the  Package  Leaflet  (PL)  as  requested  by  the 
CPMP  following  the  assessment  of  a  pharmaceutical  Follow-up  Measure  related  to  the 
manufacturing  process.  Information  regarding  the  possibility  of  Puregon  to  contain  traces  of 
streptomycin and/or neomycin that may cause hypersensitivity reactions was included in these 
sections.  In  addition,  section  4.8  of  the  SPC  and  section  4  of  the  PL  were  updated  to  include 
information regarding the occurrence of rash and erythema based on data from post-marketing 
experience and assessment of the 6th PSUR. Moreover, other minor changes were introduced in 
the SPC and PL. The procedure started on 31 May 2002. The CPMP, on 25 July 2002, adopted 
a  positive  Opinion  on  this  Type  II  variation.  The  Commission  Decision  amending  Annex  AI 
and IIIB was issued on 28 October 2002. 
4/4 
EMEA 2005 
 
 
 
 
 
 
 
